Arzerra (ofatumumab)

To address this, we employed a molecular modeling strategy using Ofatumumab, a fully human monoclonal antibody, as the framework for engineering CAR-scFvs, focusing on their binding mode, stability, and affinity towards membrane-bound CD20...Notably, binding energy calculations indicated higher binding affinity of scFv-Whitlow (-37.12 kcal/mol) for CD20 compared to scFv-G4S3 (-27.97 kcal/mol), highlighting its superior interaction dynamics. These findings position scFv-Whitlow as a promising candidate for anti-CD20 CAR-T cell therapy and provide valuable insights for the rational design of next-generation CAR constructs targeting CD20.

P2, N=135, Completed, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Sep 2025 | Active, not recruiting --> Completed

P4, N=60, Not yet recruiting, Beijing An Ding Hospital, Capital Medical University; Beijing An Ding Hospital, Capital Medical University

P2, N=42, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027

CLL has demonstrated acquired resistance to BTK inhibitors and BCL2 inhibitors, necessitating the development and evaluating of treatment options beyond their use. Cancer immunotherapies such as bispecific antibodies and chimeric T cell therapies present with viable therapies for CLL. Novel agents have also been developed that enhance the cytotoxic effect of T cells. Future studies may focus on the developing treatments that overcome the acquired resistance that results when treatment with standard of care targeted therapies ibrutinib and venetoclax.

P2, N=45, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Sep 2024

P2, N=135, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026

P3, N=200, Not yet recruiting, the First People's Hospital of Changzhou; the First People's Hospital of Changzhou

P3, N=200, Recruiting, The First People's Hospital of Changzhou | Active, not recruiting --> Recruiting

P3, N=200, Active, not recruiting, The First People's Hospital of Changzhou

P2, N=19, Completed, Gruppo Italiano Malattie EMatologiche dell'Adulto | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Apr 2024 | Trial primary completion date: Aug 2025 --> Apr 2024

Combining TDI-DNA-PAINT and LLS microscopy on immunological B cells revealed the oligomeric states and interaction of endogenous CD20 with the therapeutic monoclonal antibodies (mAbs) rituximab, ofatumumab, and obinutuzumab. Our results demonstrate that CD20 is abundantly expressed on microvilli that bind mAbs, which leads to an antibody concentration-dependent B cell polarization and stabilization of microvilli protrusions. These findings could aid rational design of improved immunotherapies targeting tumor-associated antigens.